Changes Announced for the LUNGVAC Trial by Ultimovacs
Oslo: Ultimovacs ASA (OSE: ULTI), a biotechnology firm dedicated to developing immunotherapeutic cancer vaccines, has made a crucial decision regarding its LUNGVAC trial. After thorough discussions with the involved investigators, the company has chosen to stop recruiting new patients for this clinical study.
Overview of the LUNGVAC Trial
The LUNGVAC trial is an investigator-initiated and randomized Phase II study that aimed to assess the efficacy of the UV1 vaccine. Targeting patients with advanced non-small cell lung cancer (NSCLC), the trial looked at UV1 in combination with either cemiplimab or pembrolizumab—both are checkpoint inhibitors commonly used as first-line treatments. Unfortunately, recruitment faced challenges due to an influx of new treatment options now available to patients with NSCLC.
Current Status of Patient Enrollment
Even though new patient recruitment has been halted, the 31 patients who have been part of the study since 2022 will continue their treatment and will be closely monitored. Ultimovacs expects to share topline data from these participants in the first half of 2025, which will offer crucial insights into how effective the vaccine is when used with established therapies.
Insights from the CEO and Future Plans
Carlos de Sousa, the CEO of Ultimovacs, acknowledged the hard work of the study investigators and the dedication of the participating patients. He highlighted the importance of adapting to evolving standards of care in NSCLC, which played a significant role in the decision to discontinue recruitment. Looking ahead, the company plans to focus on analyzing the data obtained to better understand UV1's effectiveness against this form of cancer.
Research Activities and Developments
While the LUNGVAC trial is currently on hold for new patient recruitment, Ultimovacs is committed to pushing forward with its other research projects. The company is evaluating UV1 in the Phase II DOVACC trial, which investigates the use of olaparib and durvalumab, with or without UV1, as a second-line treatment for high-grade BRCA negative ovarian cancer. They aim to produce topline results from this trial soon.
Innovative Approaches in Cancer Treatment
In addition to the LUNGVAC trial, Ultimovacs is exploring a novel drug conjugation platform designed to broaden its treatment options. This innovative technology aims to facilitate the development of new drug conjugates that can tackle different cancer types and enhance the therapeutic properties of treatments. An update on this exciting technology is expected before the end of the year.
Understanding the Role of UV1 in Cancer Therapy
UV1 serves as a universal cancer vaccine engineered to provoke T cell responses against telomerase, an enzyme commonly found in many cancer cells. By utilizing synthetic peptides, UV1 aims to stimulate an immune response that could lead to better outcomes for patients across various types of cancer. Notably, unlike some therapeutic methods, UV1 can be administered to a wide range of patients without requiring prior HLA screening, making it more accessible.
About Ultimovacs
Ultimovacs is an innovative biotechnology company focused on creating cutting-edge immunotherapies aimed at treating cancer. Its investigational product, UV1, seeks to amplify the benefits of immunotherapy to improve treatment responses for cancer patients. Currently, Ultimovacs is conducting extensive clinical trials involving over 750 participants across various cancer types, primarily in the U.S., Europe, and Australia.
For any inquiries, you can reach out to Ultimovacs via:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Frequently Asked Questions
Why was the recruitment for the LUNGVAC trial discontinued?
The recruitment was mainly halted due to difficulties in finding patients, which arose because of the new treatments now available for those with NSCLC.
What will happen to currently enrolled patients?
Patients already in the study will continue to receive treatment, and their outcomes will be analyzed, with topline data expected to be available in 2025.
What other research projects is Ultimovacs pursuing?
Besides the LUNGVAC trial, Ultimovacs is working on the DOVACC trial, focusing on ovarian cancer, as well as developing a new drug conjugation platform for future therapies.
How does UV1 function as a cancer vaccine?
UV1 works by targeting telomerase to stimulate the immune system, leading to a T cell response against cancer cells, which in turn may enhance treatment success.
What areas do Ultimovacs' clinical trials cover?
Ultimovacs has a wide-ranging clinical development program involving trials for melanoma, mesothelioma, head and neck cancer, ovarian cancer, and NSCLC.
